ELI
OCUL icon

Empire Life Investments’s Ocular Therapeutix OCUL Stock Holding History

Empire Life Investments’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.37M Buy
884,297
+344,182
+64% +$3.28M 0.45% 59
2025
Q4 		$6.56M Buy
540,115
+288,853
+115% +$3.51M 0.37% 63
2025
Q3 		$2.94M Buy
+251,262
New +$3M 0.17% 83

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Empire Life Investments's OCUL Position: Q1 2026 in Review

Empire Life Investments increased its Ocular Therapeutix (OCUL) stake by 64% in Q1 2026, buying an estimated $3.28M and bringing the position to 884,297 shares worth $7.37M. The position accounts for 0.45% of the portfolio, ranked #59.

Empire Life Investments first reported a position in OCUL in Q3 2025 and has held it in 3 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Empire Life Investments held 884,297 shares of Ocular Therapeutix worth $7.37M as of Q1 2026.
  • Empire Life Investments bought 344,182 Ocular Therapeutix shares in Q1 2026, an estimated $3.28M.
  • Ocular Therapeutix made up 0.45% of Empire Life Investments's portfolio in Q1 2026, its #59 holding.
  • Empire Life Investments first reported a position in Ocular Therapeutix in Q3 2025 and has held it in 3 quarters since.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Empire Life Investments's 13F filing for Q1 2026, filed 11 May 2026.